# Study on the Effect and Mechanism of Lupatadine Fumarate in the Treatment of Allergic Rhinitis

> **NCT06709092** · NA · RECRUITING · sponsor: **Cheng Lei** · enrollment: 60 (estimated)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **DRUG:** lupatadine fumarate (Luso®, Yangzijiang Pharmaceuticals)

## Key facts

- **NCT ID:** NCT06709092
- **Lead sponsor:** Cheng Lei
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-01
- **Primary completion:** 2024-12
- **Final completion:** 2026-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06709092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06709092, "Study on the Effect and Mechanism of Lupatadine Fumarate in the Treatment of Allergic Rhinitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06709092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*